FDA to review Xeris’ glucagon rescue pen auto-injector

Xeris Pharmaceuticals (NSDQ:XERS) said today that the FDA accepted its new drug application for a ready-to-use liquid glucagon rescue pen device.

The company’s product is designed to treat severe hypoglycemia in people with diabetes. The FDA is slated to make a decision about Xeris’ pen by June 10, 2019.

Get the full story at our sister site, Drug Delivery Business News.

The post FDA to review Xeris’ glucagon rescue pen auto-injector appeared first on MassDevice.

from MassDevice https://ift.tt/2z0yzha